Conatus Pharmaceuticals (CNAT) Tops Q4 EPS by 16c

Conatus Pharmaceuticals (NASDAQ: CNAT) reported Q4 EPS of ($0.34), $0.16 better than the analyst estimate of ($0.50).

For earnings history and earnings-related data on Conatus Pharmaceuticals (CNAT) click here.

You May Also Be Interested In

• LeonaBio (LONA) Price Target Cut to $17 by Citizens Amid Pipeline Development
• Huazhu Group Limited (HTHT) Tops Q2 EPS by 37c
• Vivos Therapeutics (VVOS) Tops Q2 EPS by 6c